Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Research shows that nearly one-third of seniors with diabetes experience some level of retinopathy. Another vision-related ...

Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial ...

BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Bell Potter has reaffirmed its speculative buy rating and $1.30 price target on the ASX stock. Win at Retirement Our latest ...